EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Small Molecules, Big Impact: Structural Innovations Driving PD‐L1 Checkpoint Modulation

Salma A Haggag, Mohammad Abdel-Halim iD, Ashraf H Abadi

Archiv der Pharmazie · 2026-06 · 359 (6)

DOI: 10.1002/ardp.70292 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Archiv der Pharmazie, online erschienen am 06.07.2026. Verfasst von Salma A Haggag und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, Faculty of Pharmacy and Biotechnology, German University in Cairo, Cairo, Egypt. Hauptthemen laut MEDLINE: B7-H1 Antigen, Immune Checkpoint Inhibitors, Neoplasms, Small Molecule Libraries. Die Arbeit nennt 84 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer immunotherapy enhances the body's ability to recognize and eliminate tumor cells, mainly by modulating immune checkpoints such as PD‐1/PD‐L1 and CTLA‐4. Monoclonal antibody inhibitors targeting PD‐1 or PD‐L1 have transformed cancer care, but their high cost, IV administration, and immune‐related toxicities have encouraged the development of small‐molecule alternatives. Early PD‐L1 small‐molecule inhibitors, pioneered by Bristol Myers Squibb, block PD‐1/PD‐L1 interactions by occupying hydrophobic pockets on PD‐L1, and SAR studies continue to refine their potency and selectivity. This review focuses on how the structural scaffolds of small‐molecule PD‐L1 inhibitors determine their mechanisms of action, protein interactions, and biological performance. We examine how different chemotypes influence dimerization of PD‐L1, disruption of PD‐1 binding, or engagement of additional immune‐modulatory pathways. Special attention is given to scaffolds capable of acting through more than one mechanism, as these may offer broader or more durable immunomodulatory effects. We also compare how scaffold design correlates with activity across in vitro assays, co‐culture immune models, and in vivo tumor systems, highlighting the physicochemical features that enable or limit translatability. Finally, we discuss emerging clinical efforts, the challenges underlying trial failures, and how refined structural design may guide the next generation of small‐molecule PD‐L1 inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

B7-H1 AntigenImmune Checkpoint InhibitorsNeoplasmsSmall Molecule LibrariesAntineoplastic AgentsHumansAnimalsStructure-Activity RelationshipImmunotherapyMolecular StructureDrug Design

Stichwörter der Autor:innen

PD‐L1 inhibitorsSAR and translational modelscheckpoint blockade mechanismssmall‐molecule immunotherapystructural scaffolds

Substanzen

B7-H1 AntigenImmune Checkpoint InhibitorsCD274 protein, humanSmall Molecule LibrariesAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Pharmaceutical Chemistry, Faculty of Pharmacy and Biotechnology, German University in Cairo, Cairo, Egypt.

ORCID-Profile: Mohammad Abdel-Halim

Zitieren

APA

Haggag, S. A., Abdel-Halim, M., & Abadi, A. H. (2026). Small Molecules, Big Impact: Structural Innovations Driving PD‐L1 Checkpoint Modulation. Archiv der Pharmazie, 359(6). https://doi.org/10.1002/ardp.70292

Vancouver

Haggag SA, Abdel-Halim M, Abadi AH. Small Molecules, Big Impact: Structural Innovations Driving PD‐L1 Checkpoint Modulation. Archiv der Pharmazie. 2026;359(6). doi:10.1002/ardp.70292

BibTeX
@article{Haggag2026,
  author = {Haggag, Salma A and Abdel-Halim, Mohammad and Abadi, Ashraf H},
  title = {Small Molecules, Big Impact: Structural Innovations Driving PD‐L1 Checkpoint Modulation},
  journal = {Archiv der Pharmazie},
  year = {2026},
  volume = {359},
  number = {6},
  doi = {10.1002/ardp.70292}
}
Kostenlos starten →